Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a material definitive agreement and other events related to a public equity offering. The report date is September 16, 2025, with the offering closing on September 17, 2025. The Company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details a best efforts public offering with the following financial terms:
- Securities Issued: 4,925,000 shares of common stock, 75,000 pre-funded warrants, 5,000,000 Series E warrants, and 5,000,000 Series F warrants.
- Offering Price: $2.00 per share (plus warrants) and $1.9999 per pre-funded warrant (plus warrants).
- Net Proceeds: Approximately $9.0 million after deducting placement agent fees and offering expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a 6.0% cash fee, a 0.5% management fee, and allowances for expenses totaling up to approximately $170,950.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the Company's operations.
Material Changes and Covenants
The transaction introduces significant dilution and new contractual obligations:
- Lock-Up Period: The Company agreed not to issue or announce the issuance of common stock or convertible securities for 30 days following the closing date, subject to exceptions.
- Variable Rate Restriction: The Company is restricted from entering into variable rate transactions for one year from the closing date.
- Beneficial Ownership Limits: Warrant holders cannot exercise rights if doing so would result in beneficial ownership exceeding 4.99% or 9.99% of outstanding shares.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to extend the Company's operating runway for working capital and general corporate purposes. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks and uncertainties. No specific financial guidance or revenue outlook was provided in this document.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to calculate dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and indemnification details.
- Confirm the exercise terms and expiration dates for Series E (5-year) and Series F (18-month) warrants.
- Monitor the Company's cash burn rate to assess the sufficiency of the $9.0 million net proceeds for stated working capital needs.